| Laboratory: | Clinical Biochemistry (SENDOUTS) | ||||
| Test Name: |
BONE ALKALINE PHOSPHATASE (ALP) - (S)
Test Code:
MIS8
|
||||
| Clinical Information: |
Test Indications: Bone Turnover / Formation Marker - Aid in managing patients with metabolic bone disease.
- Monitor response to antiresorptive therapy in postmenopausal women and individuals with osteoporosis Note: Does not replace bone mineral density (BMD) screening to diagnose osteoporosis. - This test is no longer recommended in the diagnosis or monitoring of Paget’s disease (see Guidelines) due to high assay cross-reactivity with liver ALP. Test Approval Requirements: Clinical Biochemist Approval Required Ordering is available only for physicians approved to use the Specialized Endocrinology Requisition (see F10-50-45D). All other requests require test approval. |
||||
| Collection Devices: |
Stability 2 days refrigerated, 2 months frozen
|
||||
| Specimen Required: |
Serum: 1.0 mL
Special Processing: Separate serum from cells within 45-60 min of collection. Specimen Stability: Ambient: 1 day (separated from cells) Refrigerated: 2 days Frozen: 2 months at -20 C |
||||
| Referral: |
Serum: 1.0 mL
Shipping & Storage: Aliquot, store and send frozen to HSC clinical Chemistry – MS5.
Testing Laboratory (MB): Referred Out Referred Out Location: Specimen referred from HSC-MS5 to: In-Common Laboratories 57 Gervais Drive North York, Ontario M3C 1Z2 Telephone: (416)422-3000 Test ID: BSALP Testing location: Mount Sinai, Toronto, ON |
||||
| Requisition: | |||||
| Reference Values: |
Reference Intervals:
Male: 0-20 ug/L Female (pre-menopausal): ≤14 ug/L Female (post-menopausal): ≤22 ug/L Method of Analysis: Chemiluminescent Immunoassay (CLIA) |
||||
| Availability: |
Within 3 Weeks
Clinical Biochemist Approval Required
|
||||
| See Also: | |||||
| More Information: |
Interpretation & Assay Interferences: Up to 20% cross-reactivity of antibodies to liver ALP with bone ALP.
Do not use hemolyzed samples as red cell enzymes may interfere with reaction. Anticoagulants, such as EDTA, citrate and oxalate inhibit ALP activity References: Frederick R. Singer, Henry G. Bone, III, David J. Hosking, Kenneth W. Lyles, Mohammad Hassan Murad, Ian R. Reid, Ethel S. Siris, Paget's Disease of Bone: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, Volume 99, Issue 12, December 2014, Pages 4408–4422 Ralston, S.H., Corral-Gudino, L., Cooper, C., Francis, R.M., Fraser, W.D., Gennari, L., Guañabens, N., Javaid, M.K., Layfield, R., O'Neill, T.W., Russell, R.G.G., Stone, M.D., Simpson, K., Wilkinson, D., Wills, R., Zillikens, M.C. and Tuck, S.P. (2019), Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline. J Bone Miner Res, 34: 579-604 e3657 |